{"id":"nimotuzumab-injection","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Acneiform rash"},{"rate":"5-15","effect":"Infusion reactions"},{"rate":"10-20","effect":"Hypomagnesemia"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"5-15","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2108359","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nimotuzumab binds to EGFR on cancer cells, preventing ligand-induced activation and downstream signaling through the PI3K/Akt and MAPK/ERK pathways. This leads to reduced cell proliferation, increased apoptosis, and enhanced radiosensitivity in EGFR-expressing tumors. Unlike some other anti-EGFR antibodies, nimotuzumab has a lower incidence of severe skin toxicity due to its lower binding affinity for EGFR.","oneSentence":"Nimotuzumab is a humanized monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:57:14.009Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Head and neck squamous cell carcinoma"},{"name":"Non-small cell lung cancer"},{"name":"Nasopharyngeal carcinoma"}]},"trialDetails":[{"nctId":"NCT07445048","phase":"PHASE3","title":"Postoperative Radiotherapy Combined With Nimotuzumab Followed by Bemcentinib in High-Risk Patients With Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2026-03-05","conditions":"Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer, Postoperative Adjuvant Treatment","enrollment":370},{"nctId":"NCT07240766","phase":"PHASE2","title":"HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2026-02-15","conditions":"Borderline Resectable Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT07353723","phase":"PHASE2","title":"Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-11-15","conditions":"Head & Neck Cancer","enrollment":10},{"nctId":"NCT07333274","phase":"PHASE3","title":"Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2026-01-05","conditions":"Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer","enrollment":335},{"nctId":"NCT06840067","phase":"NA","title":"Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.","status":"RECRUITING","sponsor":"Gansu Wuwei Tumor Hospital","startDate":"2025-03-01","conditions":"Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable","enrollment":62},{"nctId":"NCT06781073","phase":"PHASE3","title":"Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma","status":"COMPLETED","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2017-07-06","conditions":"Cervical Squamous Cell Carcinoma, Persistent","enrollment":118},{"nctId":"NCT06771596","phase":"PHASE2","title":"Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-05-12","conditions":"Uterine Cervical Neoplasms","enrollment":43},{"nctId":"NCT02428764","phase":"PHASE2","title":"Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2015-04-01","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT06718205","phase":"PHASE2","title":"Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2023-03-08","conditions":"Esophageal Cancer","enrollment":112},{"nctId":"NCT05978050","phase":"PHASE3","title":"Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2024-08-01","conditions":"Gastric or Esophagogastric Junction Adenocarcinoma","enrollment":354},{"nctId":"NCT06561763","phase":"PHASE3","title":"TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-20","conditions":"High Risk Locally Advanced Nasopharyngeal Carcinoma","enrollment":416},{"nctId":"NCT06343116","phase":"PHASE3","title":"Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2024-04","conditions":"Refractory Metastatic Colorectal Cancer","enrollment":420},{"nctId":"NCT04235114","phase":"PHASE1, PHASE2","title":"Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)","status":"RECRUITING","sponsor":"University of Saskatchewan","startDate":"2020-02-01","conditions":"Lung Cancer, Colorectal Cancer","enrollment":14},{"nctId":"NCT06039891","phase":"PHASE2","title":"Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-10-01","conditions":"Cervical Cancer","enrollment":55},{"nctId":"NCT06022276","phase":"NA","title":"Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors","status":"UNKNOWN","sponsor":"Tianjin Medical University Second Hospital","startDate":"2022-12-01","conditions":"Solid Tumor, EGFR Amplification","enrollment":46},{"nctId":"NCT03413579","phase":"PHASE3","title":"Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom","status":"COMPLETED","sponsor":"El Kendi Pharmaceuticals Manufacturing Company","startDate":"2015-11","conditions":"Cervical Cancer","enrollment":37},{"nctId":"NCT03766178","phase":"PHASE2","title":"Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2021-09","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT04833205","phase":"PHASE2","title":"Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer","status":"UNKNOWN","sponsor":"Hui Bu","startDate":"2021-04-19","conditions":"Leptomeningeal Metastasis, Lung Cancer","enrollment":30},{"nctId":"NCT04678791","phase":"NA","title":"Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2020-12","conditions":"Cervical Squamous Cell Carcinoma","enrollment":286},{"nctId":"NCT04664244","phase":"PHASE2","title":"Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma","status":"UNKNOWN","sponsor":"Lei Li","startDate":"2020-12-19","conditions":"Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor","enrollment":43},{"nctId":"NCT03469531","phase":"PHASE2","title":"Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2018-03-20","conditions":"Neoplasms, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma in Situ","enrollment":100},{"nctId":"NCT02945267","phase":"PHASE4","title":"Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2016-09","conditions":"Unresectable Pancreatic Cancer","enrollment":60},{"nctId":"NCT02611700","phase":"PHASE3","title":"Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2015-11","conditions":"Esophageal Squamous Cell Carcinomas","enrollment":504},{"nctId":"NCT02293356","phase":"PHASE4","title":"Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2015-08","conditions":"Nasopharyngeal Carcinoma","enrollment":2000},{"nctId":"NCT01938105","phase":"PHASE2","title":"Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer","status":"UNKNOWN","sponsor":"People's Hospital of Guangxi Zhuang Autonomous Region","startDate":"2013-07","conditions":"Locally Advanced Cervical Cancer","enrollment":40},{"nctId":"NCT01180166","phase":"PHASE2","title":"Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2010-05","conditions":"Gastric Cancer, Concurrent Chemoradiotherapy","enrollment":30},{"nctId":"NCT01382745","phase":"PHASE2","title":"Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers","status":"TERMINATED","sponsor":"Dr. Te Vuong","startDate":"2012-01","conditions":"Squamous Cell Carcinoma of Anal Canal","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Taixinsheng","Nimotuzumab"],"phase":"marketed","status":"active","brandName":"Nimotuzumab Injection","genericName":"Nimotuzumab Injection","companyName":"Biotech Pharmaceutical Co., Ltd.","companyId":"biotech-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nimotuzumab is a humanized monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival. Used for Head and neck squamous cell carcinoma, Non-small cell lung cancer, Nasopharyngeal carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}